HIV/AIDS Testing

Global HIV/AIDS Testing Market to Reach US$5.8 Billion by 2030

The global market for HIV/AIDS Testing estimated at US$4.1 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. HIV/AIDS Testing Instruments, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the HIV/AIDS Testing Kits & Reagents segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.7% CAGR

The HIV/AIDS Testing market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

HIV/AIDS Testing  - Key Trends and Drivers

The landscape of HIV/AIDS testing has seen significant advancements driven by global health initiatives, technological improvements, and heightened awareness of the importance of early detection. Initiatives from international organizations such as the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) aim to end the HIV/AIDS epidemic and have significantly driven the expansion of HIV testing services. Many countries have implemented national policies that mandate or encourage regular HIV testing in high-risk populations and the general public, supported by government-backed screening programs that often offer free or subsidized testing. These efforts, along with public education campaigns, have increased testing coverage and frequency, helping to destigmatize the disease and encourage more people to seek testing.

Technological advancements in HIV testing are rapidly enhancing the accessibility, accuracy, and convenience of these diagnostic methods. Modern technologies such as point-of-care tests, self-testing kits, and innovative diagnostic platforms like Next-Generation Sequencing (NGS) and CRISPR-based diagnostics are transforming HIV diagnostics. These technologies not only allow for earlier detection following exposure but also expand testing beyond traditional healthcare settings, reaching broader populations. Furthermore, the integration of artificial intelligence is streamlining the diagnostic process, enhancing early detection, and personalizing treatment strategies, which are crucial for improving patient outcomes.

The rise of self-testing kits and mobile health units is particularly notable in increasing accessibility to HIV testing. Self-testing kits offer a private, convenient option that is appealing in regions where there is significant stigma associated with HIV, increasing testing rates among populations that might otherwise avoid traditional settings. Mobile health units extend the reach of HIV testing into remote or underserved areas, further expanding access to essential diagnostic services. Additionally, the integration of telehealth and digital platforms for pre-test and post-test counseling, result tracking, and management enhances the efficiency and confidentiality of the testing process. These technological and service delivery innovations are set to continue driving the global fight against the HIV/AIDS epidemic, improving the landscape of public health with regards to HIV/AIDS management and prevention.

SCOPE OF STUDY:

The report analyzes the HIV/AIDS Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Instruments, Kits & Reagents); End-Use (Diagnostics Laboratories, Hospitals, Research Institutes, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 12 Featured) -

• Abbott Molecular, Inc.
• Abbott Molecular, Inc.
• Bio-Rad Laboratories, Inc.
• Chembio Diagnostic Systems, Inc.
• F. Hoffmann-La Roche AG
• Hologic, Inc.
• OraSure Technologies, Inc.
• Siemens Healthineers

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.